, Hans Øverlandsvei 24 A, Høvik, 1363, Høvik, Oslo, Norway.
Department of Digestive Surgery, Akershus University Hospital, 1478, Lørenskog, Norway.
Updates Surg. 2024 Sep;76(5):1635-1639. doi: 10.1007/s13304-024-01941-0. Epub 2024 Jul 14.
The paucity of prospective data on the subject of Watch and Wait for rectal cancer prompted the implementation of Norwait, a population-based study including rectal cancer patients after neoadjuvant therapy. The aim of the study was to assess the accuracy of clinical complete response (cCR) and quantify the regrowth rates. Norwait was a prospective population-based observational study with ethical approval (2017/935) registered at clinicaltrials.com (NTC03402477). Residents of Norway with histologically proven rectal cancer located within 15 cm from anal verge were eligible following completion of radiotherapy or chemoradiation at seven hospitals. cCR was the disappearance of tumour and of any ulcer with/without the appearance of whitening of prior tumour site and telangiectasia evaluated at 12 weeks by digital rectal exam, and endoscopic imaging. The study aimed to include 100 cCR patients with regrowth rates as primary endpoint. The data are presented in crude form. Eighty-two patients were included in seven hospitals from 2018 to 2020 when the study was terminated. Fifty-one patients were included in six hospitals, whereas protocol violations were identified in one hospital, where thirty-one (rather than protocol-estimated 12) patients were enrolled. Amongst the 31 patients, there were only 2 with documented cCR. Of the latter 29, there were 16 with ulcer or persistent tumour, and 13 without any documentation of cCR. Of these, 23 underwent surgery with a delay up to 50 weeks. At median 54-month follow-up of 31 patients, there were 77% local regrowths (n = 23), 40% metachronous metastases (n = 12) and 23% deaths (n = 7). At median 54-month follow-up of 51 cCR patients, there were 53% local regrowths (n = 27), 14% metachronous metastases (n = 7) and 4% deaths (n = 2). Norwait admonishes a word of caution reaching beyond the inconclusive results of a population-based study jeopardised by serious violation to protocol and legislation for conducting safe research.
由于缺乏关于直肠癌观察等待的前瞻性数据,促使实施了 Norwait 研究,该研究是一项基于人群的研究,纳入了新辅助治疗后的直肠癌患者。该研究的目的是评估临床完全缓解(cCR)的准确性,并量化肿瘤的再生长率。Norwait 是一项基于人群的前瞻性观察研究,经过伦理批准(2017/935),在 clinicaltrials.com 上注册(NTC03402477)。在七家医院接受放疗或放化疗后,挪威居民中经组织学证实的位于肛缘 15cm 以内的直肠癌患者符合入组条件。cCR 是指肿瘤和任何溃疡的消失,伴有/不伴有先前肿瘤部位的变白和毛细血管扩张,在 12 周时通过直肠指检和内镜成像进行评估。该研究旨在纳入 100 例 cCR 患者作为主要终点,评估肿瘤的再生长率。数据以原始形式呈现。2018 年至 2020 年,该研究结束时,来自七家医院的 82 例患者纳入研究。六家医院纳入了 51 例患者,而一家医院存在方案违规,有 31 例(而不是方案估计的 12 例)患者入组。在这 31 例患者中,只有 2 例有明确的 cCR。在这 29 例患者中,有 16 例存在溃疡或持续肿瘤,13 例没有任何 cCR 的记录。其中 23 例患者接受了手术,延迟时间最长达 50 周。在 31 例患者的中位随访 54 个月时,有 77%(23 例)发生局部复发,40%(12 例)发生远处转移,23%(7 例)死亡。在 51 例 cCR 患者的中位随访 54 个月时,有 53%(27 例)发生局部复发,14%(7 例)发生远处转移,4%(2 例)死亡。Norwait 提醒人们注意,这项基于人群的研究结果不确定,并且由于严重违反研究安全的方案和法规,该研究结果存在风险。